Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent

被引:42
作者
Appledorn, D. M. [1 ,2 ]
Kiang, A. [3 ]
McBride, A. [1 ,2 ]
Jiang, H. [3 ]
Seregin, S. [1 ,2 ]
Scott, J. M. [1 ,2 ]
Stringer, R. [1 ,2 ]
Kousa, Y. [1 ,2 ]
Hoban, M. [1 ,2 ]
Frank, M. M. [3 ]
Amalfitano, A. [1 ,2 ]
机构
[1] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48823 USA
[2] Michigan State Univ, Dept Pediat, E Lansing, MI 48823 USA
[3] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA
关键词
vaccine; innate immunity; serotype; adenovirus;
D O I
10.1038/gt.2008.18
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alternative human and non-human Ad serotype vectors are currently studied for gene therapy and/or vaccine applications to capitalize upon their likely ability to avoid pre-existing immunity to HAd5. However, relatively little attention has been given to the nature and scope of innate immune responses generated by alternative Ad serotypes. In this study, we characterized several innate immune responses after intravenous administration of wild-type Ad serotypes HAd31, HAd3, HAd5, HAd37, SAd23 and HAd41, representing groups A-F, respectively. Notably, biodistribution studies revealed significant differences between the serotypes, with high levels of HAd3 genomes found in the liver and lung, and HAd37 genomes found in the spleen after systemic administration. Relative to similar treatments with other Adserotypes, HAd3 and SAd23 induced altered innate immune responses, illustrated by induction of higher levels of cellular gene transcription in several tissues, and higher plasma levels of cytokines and chemokines. We also investigated whether complement interactions have a role in HAd3- and SAd23-induced responses. We confirmed complement dependent gene transcription, plasma cytokine/chemokine responses, and liver toxicities incurred after administration of HAd3 and SAd23. This study highlights the potential benefits and/or limitations to the proposed use of alternative Ad serotypes for gene therapy or vaccine applications.
引用
收藏
页码:885 / 901
页数:17
相关论文
共 79 条
  • [1] Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
    Abbink, Peter
    Lemckert, Angelique A. C.
    Ewald, Bonnie A.
    Lynch, Diana M.
    Denholtz, Matthew
    Smits, Shirley
    Holterman, Lennart
    Damen, Irma
    Vogels, Ronald
    Thorner, Anna R.
    O'Brien, Kara L.
    Carville, Angela
    Mansfield, Keith G.
    Goudsmit, Jaap
    Havenga, Menzo J. E.
    Barouch, Dan H.
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (09) : 4654 - 4663
  • [2] Construction of an adenovirus type 7a E1A(-) vector
    Abrahamsen, K
    Kong, HL
    Mastrangeli, A
    Brough, D
    Lizonova, A
    Crystal, RG
    FalckPedersen, E
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (11) : 8946 - 8951
  • [3] Adenovirus type 37 binds to cell surface sialic acid through a charge-dependent interaction
    Arnberg, N
    Kidd, AH
    Edlund, K
    Nilsson, J
    Pring-Åkerblom, P
    Wadell, G
    [J]. VIROLOGY, 2002, 302 (01) : 33 - 43
  • [4] Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene:: Application in epidemiologic studies and in the design of adenovector vaccines
    Aste-Amézaga, M
    Bett, AJ
    Wang, FB
    Casimiro, DR
    Antonello, JM
    Patel, DK
    Dell, EC
    Franlin, LL
    Dougherty, NM
    Bennett, PS
    Perry, HC
    Davies, ME
    Shiver, JW
    Keller, PM
    Yeager, MD
    [J]. HUMAN GENE THERAPY, 2004, 15 (03) : 293 - 304
  • [5] INVITRO AND INVIVO SYNTHESIS OF THE HEPATITIS-B VIRUS SURFACE-ANTIGEN AND OF THE RECEPTOR FOR POLYMERIZED HUMAN-SERUM ALBUMIN FROM RECOMBINANT HUMAN ADENOVIRUSES
    BALLAY, A
    LEVRERO, M
    BUENDIA, MA
    TIOLLAIS, P
    PERRICAUDET, M
    [J]. EMBO JOURNAL, 1985, 4 (13B) : 3861 - 3865
  • [6] Current strategies and future directions for eluding adenoviral vector immunity
    Bangari, Dinesh S.
    Mittal, Suresh K.
    [J]. CURRENT GENE THERAPY, 2006, 6 (02) : 215 - 226
  • [7] Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5
    Bergelson, JM
    Cunningham, JA
    Droguett, G
    KurtJones, EA
    Krithivas, A
    Hong, JS
    Horwitz, MS
    Crowell, RL
    Finberg, RW
    [J]. SCIENCE, 1997, 275 (5304) : 1320 - 1323
  • [8] BERKNER KL, 1984, NUCLEIC ACIDS RES, V12, P1925
  • [9] Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Cebere, I
    Dorrell, L
    McShane, H
    Simmons, A
    McCormack, S
    Schmidt, C
    Smith, C
    Brooks, M
    Roberts, JE
    Darwin, SC
    Fast, PE
    Conlon, C
    Rowland-Jones, S
    McMichael, AJ
    Hanke, T
    [J]. VACCINE, 2006, 24 (04) : 417 - 425
  • [10] Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors
    Cerullo, Vincenzo
    Seiler, Michael P.
    Mane, Viraj
    Brunetti-Pierri, Nicola
    Clarke, Christian
    Bertin, Terry K.
    Rodgers, John R.
    Lee, Brendan
    [J]. MOLECULAR THERAPY, 2007, 15 (02) : 378 - 385